Discovery Labs to Host Conference Call to Discuss Third Quarter 2013 Results on Wednesday, November 13, 2013

 Discovery Labs to Host Conference Call to Discuss Third Quarter 2013 Results
                       on Wednesday, November 13, 2013

PR Newswire

WARRINGTON, Pa., Nov. 8, 2013

WARRINGTON, Pa., Nov. 8, 2013 /PRNewswire/ --Discovery Laboratories, Inc.
(Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a
new standard of respiratory critical care,  will host a conference call at
10:00a.m. ET on Wednesday, November 13, 2013 to discuss the third quarter
financial results and other business updates. A question-and-answer session
will follow managements' remarks. The Company will report third quarter 2013
results on Tuesday, November 12, 2013 after the close of the U.S. financial

To access the conference call and participate in the question-and-answer
session, the number for domestic callers is (877) 870-4263 and for
international callers (412) 317-0790.The conference call replay number is
(877) 344-7529 or (412) 317-0088. The passcode for the replay is 10036729.

The audio webcast of the conference call will be available on the Discovery
Labs website at is recommended that participants log
onto the audio webcast at least 15 minutes prior to the call.A replay of the
audio webcast will be available after the call at the Company's website.

About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on
advancing a new standard in respiratory critical care.Discovery Labs'
technology platforms include its novel proprietary KL4 surfactant, a
synthetic, peptide-containing surfactant that is structurally similar to
pulmonary surfactant, and its proprietary drug delivery technologies being
developed to enable efficient delivery of aerosolized KL4 surfactant and other
inhaled therapies.Discovery Labs' strategy is initially focused on
neonatology and improving the management of respiratory distress syndrome
(RDS) in premature infants. Discovery Labs believes that its RDS product
portfolio has the potential to become the new standard of care for RDS and,
over time, enable the treatment of a significantly greater number of premature
infants who could benefit from surfactant therapy but are currently not

For more information, please visit the Company's website at

SOURCE Discovery Laboratories, Inc.

Contact: Investor Relations: Michael Rice, LifeSci Advisors - 646.597.6979,
Company: John Tattory, Vice President, Finance, Discovery Labs - 215.488.9418
Press spacebar to pause and continue. Press esc to stop.